Ixinity FDA Approval History
FDA Approved: Yes (First approved April 29, 2015)
Brand name: Ixinity
Generic name: coagulation factor IX (recombinant)
Company: Emergent BioSolutions Inc.
Treatment for: Hemophilia B
Ixinity (coagulation factor IX (recombinant)) is a clotting factor IX therapy indicated to prevent bleeding in patients with hemophilia B.
Development timeline for Ixinity
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.